THE MM-021 CHINA REGISTRATION TRIAL: A PHASE 2 STUDY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN CHINESE RELAPSED/REFRACTORY MYELOMA PATIENTS

被引：0
|
作者：
Hou, J. [1 ]
Du, X. [2 ]
Jin, J. [3 ]
Cai, Z. [3 ]
Chen, F. [4 ]
Zhou, D. [5 ]
Yu, L. [6 ]
Ke, X. [7 ]
Li, X. [8 ]
Wu, D. [9 ]
Meng, F. [10 ]
Ai, H. [11 ]
Zhang, J. [12 ]
Chen, N. [12 ]
Mei, J. [12 ]
Wang, J. [13 ]
机构：
[1] Shanghai Changzheng Hosp, Shanghai, Peoples R China
[2] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[4] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
[5] Beijing Union Med Coll Hosp, Beijing, Peoples R China
[6] 301 Mil Hosp, Beijing, Peoples R China
[7] Peking Univ, Hosp 3, Beijing, Peoples R China
[8] Shanghai Sixth Peoples Hosp, Shanghai, Peoples R China
[9] Suzhou Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[10] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
[11] 307 PLA Hosp, Beijing, Peoples R China
[12] Celgene Corporat, Summit, NJ USA
[13] Changhai Hosp, Shanghai, Peoples R China
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P813
引用
收藏
页码：341 / 341
页数：1
相关论文
共 50 条
  • [21] Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Lonial, Sagar
    Vij, Ravi
    Harousseau, Jean-Luc
    Facon, Thierry
    Moreau, Philippe
    Mazumder, Amitabha
    Kaufman, Jonathan L.
    Leleu, Xavier
    Tsao, L. Claire
    Westland, Christopher
    Singhal, Anil K.
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1953 - 1959
  • [22] Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
    Siegel, David S.
    Schiller, Gary J.
    Song, Kevin W.
    Agajanian, Richy
    Stockerl-Goldstein, Keith
    Kaya, Hakan
    Sebag, Michael
    Samaras, Christy
    Malek, Ehsan
    Talamo, Giampaolo
    Seet, Christopher S.
    Mouro, Jorge
    Pierceall, William E.
    Zafar, Faiza
    Chung, Weiyuan
    Srinivasan, Shankar
    Agarwal, Amit
    Bahlis, Nizar J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (04) : 501 - 510
  • [23] Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study
    Lonial, S.
    Vij, R.
    Harousseau, J.
    Facon, T.
    Moreau, P.
    Leleu, X.
    Westland, C.
    Singhal, A. K.
    Jagannath, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma
    Wang, Chunling
    He, Zhengmei
    Shi, Yuye
    Zhang, Lijuan
    Chen, Yue
    Chen, Zhi
    Yu, Liang
    HEMATOLOGY, 2017, 22 (02) : 88 - 92
  • [25] Impact of Lenalidomide Plus Low-Dose Dexamethasone Treatment on Immune Cell Populations of the Patients with Refractory/Relapsed Multiple Myeloma
    Lee, Sung-Eun
    Lim, Ji-Young
    Ryu, Da-Bin
    Kim, Tae Woo
    Jeon, Young-Woo
    Yoon, Jae-Ho
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Lee, Seok
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong Wook
    Min, Woo-Sung
    Min, Chang-Ki
    BLOOD, 2015, 126 (23)
  • [26] A PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: THE MM-011 TRIAL
    Hagiwara, S.
    Okamoto, S.
    Matsue, K.
    Iida, S.
    Sunami, K.
    Komeno, T.
    Suzuki, K.
    Ando, K.
    Taniwaki, M.
    Tobinai, K.
    Chou, T.
    Kaneko, H.
    Iwasaki, H.
    Uemura, C.
    Tamakoshi, H.
    Zaki, M. H.
    Doerr, T.
    Kuroda, Y.
    Ichinohe, T.
    HAEMATOLOGICA, 2016, 101 : 790 - 790
  • [27] A STATISTICAL COMPARISON OF THE EFFICACY AND SAFETY OF LOW-DOSE LENALIDOMIDE plus LOW- DOSE DEXAMETHASONE WITH FULL-DOSE LENALIDOMIDE plus DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Quach, H.
    Fernyhough, L.
    Henderson, R.
    Corbett, G.
    Honemann, D.
    Blacklock, H.
    Browett, P.
    Link, E.
    Cowan, L.
    Li, J.
    Swern, A.
    Hussein, M.
    Lynch, K.
    Dimopoulos, M.
    Prince, M.
    HAEMATOLOGICA, 2012, 97 : 350 - 351
  • [28] Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study
    Lonial, Sagar
    Vij, Ravi
    Harousseau, Jean-Luc
    Facon, Thierry
    Moreau, Philippe
    Leleu, Xavier
    Mazumder, Amitabha
    Kaufman, Jonathan L.
    Westland, Christopher E.
    Tsao, Claire
    Singhal, Anil K.
    Jagannath, Sundar
    BLOOD, 2010, 116 (21) : 805 - 806
  • [29] Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome
    Cai, Qian-Qian
    Wang, Chen
    Cao, Xin-Xin
    Cai, Hao
    Zhou, Dao-Bin
    Li, Jian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (04) : 325 - 330
  • [30] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
    Bahlis, Nizar J.
    Sutherland, Heather
    White, Darrell
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Venner, Christopher P.
    Gasparetto, Cristina
    Del Col, Aldo
    Neri, Paola
    Reece, Donna
    Kauffman, Michael
    Shacham, Sharon
    Unger, T. J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    Chen, Christine
    BLOOD, 2018, 132 (24) : 2546 - 2554
12345